Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 57.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of Monivent AB was 57.50% per year. The lowest was -45.80% per year. And the median was -14.70% per year.
Monivent AB (XSAT:MONI) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Monivent AB 5-Year EBITDA Growth Rate Related Terms
XSAT:MONI vs ABT, SYK, MDT: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Monivent AB's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monivent AB 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Monivent AB's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Monivent AB's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 34.80% mean?
Monivent AB (XSAT:MONI) has a 5-Year EBITDA Growth Rate of 34.80% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Monivent AB and its competitors.
Is Monivent AB's 5-Year EBITDA Growth Rate too high?
Monivent AB's current 5-Year EBITDA Growth Rate is 34.80%. Overall, Monivent AB has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monivent AB's 5-Year EBITDA Growth Rate compare to ABT and SYK?
Monivent AB's 5-Year EBITDA Growth Rate of 34.80% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Monivent AB and its competitors. Monivent AB's current 5-Year EBITDA Growth Rate is 34.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monivent AB stock overvalued right now?
Based on GuruFocus' analysis, Monivent AB (XSAT:MONI) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.05, compared to a current price of kr0.16 — trading 220% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 34.80%. Monivent AB's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Monivent AB (XSAT:MONI), the current 5-Year EBITDA Growth Rate is 34.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monivent AB (XSAT:MONI) Overvalued in 2026?
Based on GuruFocus' analysis, Monivent AB stock appears to be overvalued.
The current stock price of kr0.16 is trading 220% above its estimated GF Value™ of kr0.05.
GuruFocus considers Monivent AB to be Significantly Overvalued.
Key valuation signals for XSAT:MONI:
5-Year EBITDA Growth Rate: 34.80%
GF Value™: kr0.05 vs. price of kr0.16 (220% above fair value)
No single metric tells the full story. See the XSAT:MONI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monivent AB is a medtech company focused on improving the care given to newborn babies in need of respiratory support at birth. The company has developed a patented solution that provides continuous feedback on the volumes of air given to the newborn during manual ventilation. The airflow is measured directly in the face mask and feedback on the ventilation parameters is displayed numerically and graphically in real-time on the external monitor. The company's product is Monivent Neo100.
22GF Score
Get the complete analysis for XSAT:MONI
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSAT:MONI has been successfully added to your 
